Skip to main content

    BTIG reiterates Buy rating on Humacyte (HUMA)

    GNG Research Market News

    By GNG Research

    On November 10, 2026, BTIG reaffirmed its Buy rating on Humacyte Inc (HUMA).

    Among two firms active over the past 90 days, one holds a bullish rating. The consensus price targets from eight analysts as of November 6, 2026, have a mean of $1.66, a median of $1.15 and a range of $0.51 to $4.20.

    Consensus Q4 FY2026 EPS is -$0.09, with revenue at $1.87 million. The next earnings report is on March 25, 2027.